PHARMYKA has a comprehensive product basket and includes Branded and Generic Formulations covering the majority of therapeutic segments for all oral dosage forms. At present, PHARMYKA is in the process of consolidating of product portfolio in selected segments and is looking to further strengthen its offerings. PHARMYKA is also concentrating its efforts to build and enhance its portfolio in the chronic health, nutraceutical, and food segment, thus creating a healthy balance of both acute and chronic therapies.
We provide comprehensive delivery of medical clinics, individual medical departments in hospitals. We are also equally acknowledged as suppliers of individual operational units, technologies, and interior fittings for healthcare.
With our strategic partners, we have been delivering Medical buildings and individual medical departments including Diagnostic rooms, central sterilization, pathology departments, oncology departments, pharmacies and pharmacology facilities, medical laboratories, anesthesiologic resuscitation units, critical care units, inpatient departments, radiology departments including supply and installation of medical furnishing, medical technology.
APIs business programs were accomplished for:
· Gemcitabine via patented route for Eli Lily
· Capecitabine for Novartis /Dolder AG
· Irinotecan and Topotecan for DSM
· Caspofungin for Pfizer
· Docetaxel and Paclitaxel via patented route for Pfizer
· Imatinib, Gefitinib, Erlotinib, and Dasatinib for DSM
More than 700 formulations GenericsBranded
Therapeutic Categories :
Anti Migraine/ Anti VertigoCough MedicineAnalgesics/ AntipyreticsAnti Asthmatic